Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

RENEW 4

Novo Nordisk · Phase 3 · Recruiting · Enrollment 285

NCT07745504

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2n/rn/rn/rn/r
Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1n/rn/rn/rn/r
Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1n/rn/rn/rn/r

Not shown

  • Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2: endpoint not reported
  • Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1: endpoint not reported
  • Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1: endpoint not reported